Gilead Compares Stribild To Prezista In Seeking Exclusivity For Fixed Dose Combinations
This article was originally published in The Pink Sheet Daily
Gilead requests five-year marketing exclusivity for two of the components in its HIV Quad treatment Stribild; citizen petition says award should not depend on whether a new active moiety is approved first as a single entity product or as part of a fixed-dose combination.
You may also be interested in...
FDA rejects requests by firms to make new policy retroactive; Gilead’s Harvoni and Eisai’s Akynzeo fixed combos, approved the day FDA issued its final guidance, granted exclusivity.
In response to citizen petitions from Gilead, Ferring and Bayer, FDA issued a draft guidance saying future fixed-combination products that include a previously approved active moiety will be eligible for five years of new chemical entity marketing exclusivity.
JT’s HIV compound comes home after being joined with Gilead combination therapy. Also approved is Nobelpharma’s glowing red in vivo diagnostic for malignant glioma.